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Multiple extrahepatic manifestations have been associated with chronic hepatitis C, the most important among them being
cryoglobulinemia, glomerulonephritis, porphyria cutanea tarda, lichen planus, seronegative arthritis, and lymphoproliferative
disorders as in the sudies of Bonkovsky and Mehta (2001) and El-Serag et al. (2002). We will discuss in this paper chronic
hepatitis C- related kidney disease and course and management of patients with chronic hepatitis C in special circumstances
like hemodialysis and kidney transplantation.
1. Cryoglobulinemia
Cryoglobulinemiaisdeﬁnedasthepresenceofimmunoglob-
ulins in serum which reversibly precipitate in vitro at low
temperatures. Hepatitis C is most commonly associated with
mixed Cryoglobulinemia (MC), which can be classiﬁed as
type II in which the precipitates contain polyclonal IgG
and monoclonal IgM with antigammaglobulin (rheumatoid
factoractivity)orTypeIIIMCinwhichprecipitatesarecom-
posed of polyclonal IgG and polyclonal IgM [3]. Up to 90%
of patients with cryoglobulinemia have anti-HCV, indicating
that the disease is not really essential, but rather related to
HCV. Cryoglobulinemia is more common in women than
men and typically occurs after decades of HCV infection;
Cryoglobulins consist of complexes of RF, IgG, anti-HCV,
and HCV virions [4]. The cause of cryoglobulinemia is not
well understood; it appears to be due to excessive prolifera-
tion of B cells induced by the chronic antigenic stimulation
of HCV infection. Frank symptomatic cryoglobulinemia
occurs in 1% or less of patients and usually is associated
with high levels of RF and cryoglobulins. In these patients,
typical symptoms are fatigue and palpable purpura, which
histologically consists of a leukocytoclastic vasculitis (with
complexes of anti-HCV and HCV in injured tissue); see
Figure 1. Typical renal manifestations of cryoglobulinemia
include proteinuria and microscopic hematuria with mild-
to-moderaterenalinsuﬃciency,andrenalhistologyrevealing
membranoproliferative glomerulonephritis (MPGN) [5].
2. HCV-RelatedGlomerular Disease
The principal renal manifestation of HCV infection is
MPGN, usually in the context of cryoglobulinemia. HCV
is probably the major cause of idiopathic MPGN. The
renal disease is rare in children and typically occurs in
patients with long-standing infection, often in association
with mild subclinical liver disease. Clinically, patients may
have symptoms of cryoglobulinemia, including palpable
purpura, arthralgias, neuropathy, and weakness. Renal man-
ifestations include nephrotic or nonnephrotic proteinuria
and microscopic hematuria [5–7]. Renal insuﬃciency is
frequently mild. Most patients will have anti-HCV, as well
as HCV RNA, in serum. Serum aminotransferase levels are
elevated in 70% of patients, and the majority have RF and
low levels of complement. Cryoglobulins are detected in
50%–70% of patients. The pathogenesis of the glomerular
injury in HCV infection is believed to result from deposition
of circulating immune complexes of HCV, anti-HCV, and
RF at the site of injury. Renal histology typically shows
lobular accentuation of the glomerular tuft with increased
mesangial cellularity and matrix, endothelial swelling, split-
ting of capillary basement membrane and intracapillary
accumulations of eosinophilic material representing precip-
itated immune complexes or cryoglobulins. On electron
microscopy, immune complexes are usually subendothelial
and may have a ﬁnely ﬁbrillar or tactoid pattern. Both
subendothelial and mesangial immune complexes can be2 Hepatitis Research and Treatment
identiﬁed by electron microscopy, typically without distinc-
tive substructure (see Figure 2). In both forms of HCV
associatedMPGN,mesangialandcapillarywalldepositionof
IgM,IgG,andC3isusually,butnotinvariablypresent.Other
forms of glomerular injury reported in patients with HCV
infection include membranous glomerulonephritis, IgA
nephropathy, postinfectious glomerulonephritis, focal and
segmental glomerulosclerosis, ﬁbrillary glomerulonephritis,
and immunotactoid glomerulopathy [6, 7]. Recurrence of
MPGN in renal allografts has been suspected in a small
number of patients [7].
3. TreatmentofHCV-RelatedCryoglobulinemia
andGlomerular Disease
Antiviral therapy with interferon alfa has been found
associated with improvements in cryoglobulins, rheumatoid
factor, and creatinine levels and improving symptoms of
immune complex disease. However, a large proportion of
patients relapse particularly with interferon monotherapy
administered for only 6 months. Long-term remission in
cryoglobulinemia can occur with interferon therapy and
response rates are similar in patients with hepatitis C
without cryoglobulinemia. Higher doses of interferon and
combination therapy with ribavirin yield greater response
rates, but relapses and nonresponses still occur [8, 9]. Long-
term maintenance interferon therapy can ameliorate the
disease in some patients in whom sustained viral eradication
is unsuccessful [10]. In patients unable to tolerate or
unresponsive to interferon therapy disease, amelioration
can been achieved by using ribavirin alone [11]. Antiviral
therapy can be successful in eradicating HCV in patients
with cryoglobulinemia or glomerulonephritis, but sustained
responsesareuncommon[12].Anti-inﬂammatory,cytotoxic
drugs and plasma exchange have been used in patients with
severeacutesystemicvasculitis,withpartialsuccess.Forthese
reasons, corticosteroids and cyclophosphamide continue to
beused,wheninterferontherapyisineﬀective[13].Although
these drugs may increase viral titers they have not been
associated with worsening of the underlying hepatic disease.
An appropriate approach to treatment of severe acute ﬂares
of cryoglobulinemia with glomerulonephritis or vasculitis
is combination antiviral therapy using peginterferon and
ribavirin for48weeks,adding corticosteroidsandcyclophos-
phamide as needed to control severe symptoms. In the
most severe cases, plasmapheresis for 2 to 3 weeks can be
helpful. Recent promising results suggest that monoclonal
antibody to B cells (anti-CD20; rituximab) may be helpful
in refractory cases [14].
4.HepatitisCinDialysis
There is considerable variability in the prevalence of anti-
HCVandchronicHCV infectionindialysis units worldwide,
ranging from as low as 1% to as high as 95%. The prevalence
rates reported in HD patients in Middle Eastern countries
are 68% in Saudi Arabia with a range of 14.5% to 94.7%
[15–17], 26% in Oman, and 80% in Egypt. The prevalence
rates reported are 1%–29% from Western Europe, 8%–36%
fromNorthAmerica,5.9%inAustralia,and44%–60%inFar
Eastern countries. There is also a great variability in HCV
testing practices in dialysis centers. With the introduction
of routine screening and heightened attention to prevention
of spread, the incidence of HCV infection has declined in
dialysis centers in many countries, but remained high in
others [18]. In the US, the prevalence of hepatitis C in the
dialysis population has not changed, and the incidence of
new cases of hepatitis C has remained constant, in the range
of 1% to 3% per year [19]. The high prevalence of HCV
in dialysis patients is of great concern in view of studies
that suggest that these patients have a higher mortality than
HCV-negativepatients[20,21].AlthoughHCVtransmission
through blood product transfusion was a signiﬁcant source
of infection previously, the current cases are more likely
related to nosocomial exposure.
The spectrum of liver disease in HCV positive HD
patients has been reported to be mild to moderate [22–
25] in most series, and a high proportion of patients had
normal ALT levels. Importantly, the proportion of patients
with advanced ﬁbrosis or cirrhosis tended to be low. In
these studies, the frequency of bridging hepatic ﬁbrosis
(stage 3) or cirrhosis (stage 4) ranged from 5% to 32%.
In most studies, there were no associations between ALT
or HCV RNA levels and severity of histological changes. In
a multicenter prospective study from Japan, 1,470 patients
(19% positive for anti-HCV) from 16 dialysis centers were
followed up for an average of 6 years. Mortality was
greater in the anti- HCV-positive group (33%) than in
controls (23%), and the excess mortality appeared to be
accounted for by deaths from cirrhosis (5.5% versus 0%)
and hepatocellular carcinoma (8.8% versus 0.4%). The RR
for death in anti- HCV-positive patients was 1.57 (95%
CI, 1.23 to 2.00). In a study from the US, 287 anti-HCV-
positive and 286 randomly selected dialysis control patients
from 14 transplant centers were assessed, with a median
followup of 7 years [23]. In multivariate analysis, RR for
death from all causes in anti-HCV-positive patients was 1.41
(95% CI, 1.01 to 1.97), and for death from liver disease
or infection, 2.39 (95% CI, 1.28 to 4.48). Death from liver
disease occurred in 14% of anti-HCV–positive and only
2% of anti-HCV–negative controls. These data show that
chronic hepatitis C adversely aﬀects survival in patients with
ESRD; cirrhosis and liver cancer account for 13% to 14% of
deaths.
5. Epidemiology of HepatitisCinDialysis
There is a considerable variation in the incidence and
prevalence of new cases of anti-HCV among dialysis centers
[19–26] 44454650 risk factors for spread include a history
of transfusions, number of blood products transfused, and
number of years on hemodialysis. Transmission of HCV, as
with HBV, depends on the presence of chronically infected
patientsandpotentialexposuretobloodandbloodproducts.
In addition to standard universal precautions, additional
practices are recommended because exposure to bloodHepatitis Research and Treatment 3
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Figure 1: (a) Classical Cryoglobulinemia-related small vessel vasculitis of lower extremities characterized by erythematosus palpable
maculopapular rashinaHCVpositivepatient (b)Cryoglobulinprecipitates inserum.theleft tubeisat roomtemperature;therighttubehas
been in the 4◦C incubator, and the cryoglobulin has precipitated out and settled to the bottom of the tube, (c) Serum protein electrophoresis
(ELP) of the cryoprecipitate reveals both a homogeneous band and a smear pattern in the gamma zone (indicating a cryoglobulin composed
of monoclonal and polyclonal gamma globulins. G: gamma, A: alpha, M: Mu, K: kappa, and L: lambda immunoglobulin bands.
(a) (b)
Figure 2: Membranoproliferative Glomerulonephritis Type I on light (a) and Electron microscopy (b). A light microscopy showing diﬀuse
endothelial proliferation B arrow pointing at subendothelial deposits on EM.
is routinely anticipated [27, 28]. These recommendations
include special dialysis unit precautions, regular serological
testing, active surveillance, and training and education.
Recommended precautions include routine use of gloves and
restriction of use of common supplies, medications, and
carts to deliver them. In addition, there should be strict
attention to cleaning and disinfecting items shared between
patients and careful disposal of dialyzers and blood tubing
after treatments. The CDC has not recommended isolation
of HCV-infected patients in dialysis units [27, 28] similarly,
HCV-infected patients need not be excluded from partici-
pating in dialyzer reuse programs. Baseline testing should4 Hepatitis Research and Treatment
include serum ALT levels and assays for both HBV and HCV
infection. For anti-HCV-negative patients, recommended
monitoring includes testing ALT levels monthly and anti-
HCV every 6 months. Elevations in ALT levels should lead
to anti-HCV testing. If ALT levels are persistently abnormal
despite the absence of anti-HCV, testing for HCV RNA by
qualitative assay (such as polymerase chain reaction) should
be considered. Dialysis patients who develop anti-HCV
should be reported to local health departments. The CDC
also recommends that dialysis units maintain surveillance
records relevant to infection control. Patient records should
include the location of the dialysis station, machine number,
and names of attending staﬀ members. Centralized records
should include logbooks or ﬁles of serological test results
and patient vaccine status. Staﬀ should be designated to
review results regularly, and a plan should be developed to
investigate new cases.
6. Therapy of HepatitisC inDialysisPatients
There are at least 17 published studies of interferon therapy
in patients with ESRD, but none is of suﬃcient size and
duration to permit deﬁnitive recommendations regarding
the beneﬁts and risks of therapy [29–41]. In addition, there
is virtually no information on the use of peginterferon
or interferon-ribavirin combination therapy. Ribavirin is
cleared by the kidneys and causes dose-related hemolysis,
which makes it contraindicated in patients with kidney
disease. For these reasons, studies of therapy in patients
with ESRD have used interferon monotherapy [42]. Studies
have ranged in size from 6 to 37 patients and used varying
formulations of interferon (alfa-2a, alfa-2b, and alfa-n1) in
varying doses (1 to 10MU) and varying regimens (usually
thrice weekly, but for periods ranging from 16 to 48 weeks).
Most studies used a 6-month posttherapy SVR as the end
point for successful therapy. Overall, 40% of treated patients
had an SVR, a rate greater than that was usually reported for
monotherapy with interferon alfa in patients with hepatitis
C without renal disease (6% to 18%). Furthermore, in
studiesthatincludedcontrolswithoutrenaldisease,response
rates were similar or greater in patients with renal disease
[30–34]. These results suggest that patients with ESRD
have a similar, if not better, likelihood of a sustained
response to interferon alfa therapy for hepatitis C than
patients without renal disease. Most studies of interferon
therapy of patients with ESRD have reported a high rate of
serious adverse events and high rates of dose modiﬁcation
and early discontinuation rate of 0%–51% averaging 26%.
Severe adverse events included pulmonary edema, cerebral
hemorrhage,acutepancreatitis,cardiomyopathy,lymphoma,
diplopia, and septic shock. Nevertheless, SVRs that have
occurred in patients with advanced renal disease appear
to be durable and clinically signiﬁcant. At present, therapy
for hepatitis C in patients with ESRD is controversial and
should be considered only in patients with signiﬁcant liver
disease, minimal other co-morbidities, and a reasonable
likelihood of prolonged survival and if renal transplantation
iscontemplated.PatientswithacutehepatitisCalsoarelikely
to be suitable candidates fortreatment.Finally, persistence of
HCV RNA despite interferon monotherapy for 8 to 12 weeks
shouldleadtoearlydiscontinuationbecausethechanceofan
SVR is highly unlikely [40, 41].
7. HepatitisCafter Renal Transplantation
The natural history of HCV in the transplant patient
population is diﬃcult to deﬁne; several studies have reported
that short-term graft and patient survival are not aﬀected
greatly by HCV infection, but long-term (10 to 20 years)
survival clearly is worse. There are a greater incidence of
ALTelevations,anincreaseinviralreplicationandoccasional
occurrence of ﬁbrosing cholestatic hepatitis and progressive
liverdiseaseinHCVpositivepatientsfollowingkidneytrans-
plant. Acquired hepatitis C de novo from an infected donor
at transplantation, coinfection with both HBV and HCV,
degree and form of immunosuppressive therapy have major
eﬀects on HCV titers after transplantation and consequently
on disease outcome. HCV-infected patients appear to have
a greater risk for diabetes mellitus and proteinuria. Several
diﬀerent renal diseases have been reported in HCV-infected
patients after kidney transplantation, including recurrent or
denovoMPGN,membranousnephropathy,minimalchange
disease, renal thrombotic microangiopathy, acute transplant
glomerulopathy, and chronic transplant glomerulopathy
[7, 42–45]. MPGN has been reported most commonly,
at rates ranging from 5% to 54% in HCV-positive renal
transplant recipients. Interferon therapy is contraindicated
in renal transplant patients due to higher incidence of acute
cellular rejection, renal failure, and graft loss [46–48]. In
exception to the prescription against interferon therapy in
renal transplant recipients is the occurrence of ﬁbrosing
cholestatic hepatitis although whether such therapy, on
balance, prolongs graft or host survival and or improves
health-related quality of life is uncertain [49]. Early studies
of ribavirin indicated that monotherapy with this oral
nucleoside analogue was associated with improvements in
ALT levels and liver histological characteristics in 30% to
50% of patients although ribavirin has little or no eﬀect
on HCV RNA levels [47, 48]. Dose-dependent hemolysis
caused by ribavirin can be severe in patients after solid-
organ transplantation. Thus, there are no clearly eﬀective
therapies for hepatitis C that can be used safely in renal
transplant recipients. In view of this limitation, there has
been an increased focus on the identiﬁcation of and therapy




Newer therapies are under trial for the treatment of chronic
hepatitis C; these drugs are either modiﬁed derivatives of
current treatments or newer drugs targeting HCV-encoded
proteins or host-encoded proteins. It is important to note
that none of these agents have so far been tested in patients
with advanced kidney disease.Hepatitis Research and Treatment 5
8.1. Albinterferon. It is a form of interferon alfa which is
genetically fused to albumin. Its advantages are its long half-
life and improved side eﬀect proﬁle [50].The results of two
pivotal phase 3 noninferiority trials have been reported in
preliminaryform.InonestudyACHIEVE1,1323treatment-
na¨ ıve patients with genotype 1 infection were randomized to
receive either albinterferon at a dose of 900μg or 1200μgt w o
weekly or conventional peginterferon alfa-2a 180μgw e e k l y ,
in combination with ribavirin [51]. The SVR rates of 48, 47,
and 51%, respectively, were recorded. The second phase 3
trial, known as ACHIEVE 2/3, included 932 treatment-na¨ ıve
patients with genotype 2/3 infection who were randomly
assignedto24weeksofalbinterferoneither900μgor1200μg
every two weeks, or peginterferon alfa-2a 180μg weekly, in
combination with ﬁxed-dose ribavirin. The SVR rates of 80,
80, and 85 percent, respectively, were noted. A dry cough was
observed in 40% of albinterferon-treated patients versus 29
percent in the peginterferon arm.
Ribavirin derivatives with a lower tendency to cause
hemolytic anemia have been studied although none has yet
been shown to be as eﬀective as ribavirin [52, 53]. Devel-
opment of levovirin has been terminated since it was found
to be inferior to ribavirin in combination with peginterferon
[54]. Similarly, taribavirin, a prodrug of ribavirin has failed
to show non-inferiority to ribavirin in two phase III trials.
8.2. Telaprevir. A NS3/4A protease inhibitor in humans has
been vigorously studied and is currently in phase III clinical
trials. The rapid emergence of viral resistance mutants to
telaprevir monotherapy resulted in subsequent clinical trials
combining telaprevir with peginterferon and ribavirin [55,
56] PROVE 1 and 2 clinical trials evaluated combination
therapy of telaprevir with peginterferon plus ribavirin in
treatment-na¨ ıve patients with chronic genotype 1 infection
[57, 58]. In PROVE 1, a total of 263 patients were randomly
assigned to one of three telaprevir groups or to a control
group. The control group received peginterferon alfa-2a (180
micrograms each week) and ribavirin for 48 weeks plus
placebo for the ﬁrst 12 weeks. The three telaprevir groups all
received the same dose of telaprevir for 12 weeks along with
either 12, 24, or 48 weeks of peginterferon plus ribavirin.
The SVR rate was signiﬁcantly higher in the 24- and 48-
week telaprevir groups compared with the control group (61
a n d6 7v e r s u s4 1p e r c e n t ,r e s p . )[ 57]. In PROVE 2 [58],
a total of 334 patients were randomized to receive either,
telaprevirandpeginterferonalfa-2afor12weeksortelaprevir
plus peginterferon plus ribavirin for 12 weeks or telaprevir
plus peginterferon plus ribavirin for 12 weeks followed
by peginterferon/ribavirin for an additional 12 weeks or
standard of care peginterferon/ribavirin for 48-weeks. SVR
was achieved in 69 and 60 percent of patients in the 24 and
12 week arms, respectively, while the SVR was 46 percent
in the standard of care 48 week arm. The diﬀerence was
statistically signiﬁcant for the comparison between the 24
week versus control arms (i.e, 69% versus 46%). Twelve
percent of patients across all telaprevir treatment arms
discontinued therapy due to skin rash [58]. A third phase 2
study called PROVE 3 studied 453 genotype 1 chronic HCV
patients who had been nonresponders or relapsers to prior
therapy with peginterferon and ribavirin [59]. Forty-three
percent of subjects had cirrhosis or bridging ﬁbrosis. The
patients were randomized to receive telaprevir for 12 weeks
plus peginterferon and ribavirin for 24 weeks, telaprevir for
24 weeks plus peginterferon and ribavirin for 48 weeks or
telaprevir for 24 weeks plus peginterferon for 24 weeks with
no ribavirin, or standard of care peginterferon and ribavirin
for 48 weeks. The overall SVR rates for the four arms were
51, 52, 23, and 14 percent, respectively. Comparing these
four arms by subgroup, the SVR rates were 69, 76, 42, and
20 percent in prior relapsers, 57, 50, 36, and 40 percent in
prior breakthroughs, and 39, 38, 10, and 9 percent in prior
nonresponders [59].
8.3. Boceprevir. It is another protease inhibitor currently
in phase III trials. A phase II study (HCV SPRINT-
1) included 595 treatment-na¨ ıve patients with genotype
1 HCV compared peginterferon alfa-2b/weight-based rib-
avirin daily for four weeks followed by the addition of
boceprevir for either 24 or 44 more weeks (lead-in),
boceprevir/peginterferon/low-dose ribavirin daily for 28
or 48 weeks (no lead-in), or standard of care peginter-
feron/ribavirin for 48 weeks. In a second part of this
study, “low-dose” ribavirin was compared with “full-dose”
ribavirin in combination with boceprevir and peginterferon
for48weeks.The48-weekboceprevirlead-ingroupachieved
an SVR rate of 75 percent versus 38 percent for the standard
of care group. The 28-week boceprevir lead-in group had an
SVR of 56 percent. The 48- and 24-week no lead-in groups
had SVR rates of 67 and 54 percent, respectively. In part 2
of SPRINT-1, the “low-dose” ribavirin group had an SVR of
only 36 percent compared to 50 percent for the “full-dose”
ribavirin group. Anemia was more common in boceprevir-
treated patients; treatment discontinuations due to adverse
events were between 10 and 26 percent for patients in the
boceprevir arms, compared to 9 percent in the control arm
[60].
8.4. Polymerase Inhibitors. Development of a number of
promising HCV polymerase inhibitors has been halted due
to their toxicity. A phase I trial of R7128 combined with
peginterferonandribavirinin50genotype1treatment-na¨ ıve
patientsyieldedanimpressive85percentrateofundetectable
HCV RNA following four weeks of treatment compared to
a 10-percent rate in patients receiving peginterferon and
ribavirin alone [61]. Another trial of R7128 with pegin-
terferon/ribavirin in 25 genotype 2/3 prior nonresponders
demonstrated a ≥86 percent rate of undetectable HCV RNA
following four weeks of treatment with no serious adverse
events [61].
8.5. Cyclophilin Inhibitors. Cyclosporin A, inhibits HCV
replication in cell culture replicon models [62]. A synthetic
nonimmunosuppressive form of cyclosporin, Debio-025,
exhibits potent activity against both HCV and HIV in
cell cultures [63]. In a phase I clinical trial of HCV-HIV
coinfected patients, the mean HCV RNA decline was −3.6
log(10) after a 14-day course of Debio-025 monotherapy6 Hepatitis Research and Treatment
[63]. No viral rebound was observed during the two-
week dosing period. A phase II trial randomly assigned
90 treatment-na¨ ıve patients to one of ﬁve diﬀerent regi-
mens for 29 days: peginterferon monotherapy, peginterferon
plus Debio-025 at three diﬀerent doses, and Debio-025
monotherapy [64]. Debio-025 had an additive antiviral
eﬀect when combined with peginterferon; among patients
with genotype 1 or 4 infection, Debio-025 or peginterferon
monotherapy resulted in mean HCV RNA declines of −2.2
log(10)IU/mLand −2.49log(10)IU/mL,respectively,while
the combination of peginterferon plus 600mg Debio-025
resulted in a mean decline of −4.61log (10)IU/mL at day 29.
8.6.Nitazoxanide. isanantiprotozoaldrugthatinhibitsboth
HBV and HCV replication in cell culture models [65]. The
mechanism of nitazoxanide activity against HCV may be
mediated by phosphorylation of the host proteins kinase R
(PKR) and eIF2alpha, which in turn inhibits HCV repli-
cation [66]. An initial trial included 50 patients who were
randomly assigned to nitazoxanide monotherapy or placebo
for 24 weeks [67]. All patients had genotype 4 infection,
SVR rate was signiﬁcantly higher with nitazoxanide (17
versus 0 percent). A follow-up trial randomly assigned 96
patients with genotype 4 infection to one of three groups:
(1) standard of care peginterferon/ ribavirin for 48 weeks;
nitazoxanide monotherapy for 12 weeks followed by either
(2) nitazoxanide/peginterferon for an additional 36 weeks or
(3) nitazoxanide/ peginterferon/ribavirin for an additional
36weeks[68].SVRrateswere79percentinthetripletherapy
arm, 61 percent in the nitazoxanide/peginterferon arm, and
50 percent in the standard of care arm. Adverse events were
similar across all three groups other than for anemia, which
was more common in the ribavirin-treated groups.
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